RIFAXIMIN PLUS LACTULOSE IS MORE EFFICACIOUS THAN LACTULOSE ALONE FOR THE PREVENTION OF OVERT HEPATIC ENCEPHALOPATHY (OHE) IN PATIENTS WITH OR WITHOUT ASCITES

被引：0
|
作者：
Kowdley, Kris V.
Reau, Nancy
Pyrsopoulos, Nikolaos T.
Allen, Christopher
Heimanson, Zeev
Sanyal, Arun J.
机构：
来源：
GASTROENTEROLOGY | 2023年 / 164卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Su1548
引用
收藏
页码：S1327 / S1327
页数：1
相关论文
共 50 条
  • [31] Genomic Characterization of Stool Microbiota With Rifaximin Monotherapy Versus Lactulose Combination Therapy for Prevention of Overt Hepatic Encephalopathy (HE) Recurrence
    Dupont, Herbert L.
    Hassanein, Tarek I.
    Sanyal, Arun J.
    Wolf, Ray A.
    Mullen, Kevin D.
    HEPATOLOGY, 2016, 64 : 720A - 721A
  • [32] Combination of rifaximin and lactulose improves clinical efficacy and mortality in patients with hepatic encephalopathy
    Wang, Zhida
    Chu, Pei
    Wang, Wenjin
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2019, 13 : 1 - 11
  • [33] Primary prophylaxis of overt hepatic encephalopathy in patients with cirrhosis: An open labeled randomized controlled trial of lactulose versus no lactulose
    Sharma, Praveen
    Sharma, Barjesh Chander
    Agrawal, Amit
    Sarin, Shiv Kumar
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2012, 27 (08) : 1329 - 1335
  • [34] THE EFFECT OF LACTULOSE ON PSYCHOMOTOR PERFORMANCE TESTS IN ALCOHOLIC CIRRHOTICS WITHOUT OVERT HEPATIC-ENCEPHALOPATHY
    MCCLAIN, CJ
    POTTER, TJ
    KROMHOUT, JP
    ZIEVE, L
    JOURNAL OF CLINICAL GASTROENTEROLOGY, 1984, 6 (04) : 325 - 329
  • [35] Clinical efficacy of lactulose in cirrhotic patients with and without subclinical hepatic encephalopathy
    Watanabe, A
    Sakai, T
    Sato, S
    Imai, F
    Ohto, M
    Arakawa, Y
    Toda, G
    Kobayashi, K
    Muto, Y
    Tsujii, T
    Kawasaki, H
    Okita, K
    Tanikawa, K
    Fujiyama, S
    Shimada, S
    HEPATOLOGY, 1997, 26 (06) : 1410 - 1414
  • [36] Real-World Experience of the One-Year Efficacy of Rifaximin Add-On to Lactulose Is Superior to Lactulose Alone in Patients with Cirrhosis Complicated with Recurrent Hepatic Encephalopathy in Taiwan
    Chang, Ching
    Huang, Chien-Hao
    Tseng, Hsiao-Jung
    Yang, Fang-Chen
    Chien, Rong-Nan
    JOURNAL OF PERSONALIZED MEDICINE, 2021, 11 (06):
  • [37] Therapeutic Efficacy of Oral PEG3350 plus Lactulose Versus Lactulose alone in Patients of Acute-on-Chronic Liver Failure with Overt Hepatic Encephalopathy: An Open Label Prospective Randomised Controlled Study
    Ahmed, Syed
    Premkumar, Madhumita
    Dhiman, Radhakrishna
    Imran, Rather
    Mishra, Saurabh
    Mehtani, Rohit
    Singh, Virendra
    Duseja, Ajay
    Taneja, Sunil
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2019, 34 : 97 - 97
  • [38] The Modest Differential Effects of Rifaximin Alone vs Rifaximin Plus Lactulose on Intestinal Microbial Diversity and Composition in Patients With Cirrhosis
    Frenette, Catherine
    Sundaram, Vinay
    Heimanson, Zeev
    Israel, Robert
    Sanyal, Arun
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2020, 115 : S517 - S518
  • [39] RISK REDUCTION IN GASTROINTESTINAL CANCERS IN CIRRHOTIC PATIENTS RECEIVING LACTULOSE, RIFAXIMIN, OR COMBINATION THERAPY FOR HEPATIC ENCEPHALOPATHY
    Patel, Ankoor H.
    Li, You
    Minacapelli, Carlos D.
    Catalano, Carolyn
    Rustgi, Vinod K.
    GASTROENTEROLOGY, 2023, 164 (06) : S1328 - S1328
  • [40] Reduction in Gastrointestinal Cancers in Cirrhotic Patients Receiving Rifaximin vs Lactulose Only Therapy for Hepatic Encephalopathy
    Patel, Ankoor H.
    Li, You
    Minacapelli, Carlos D.
    Catalano, Kaitlyn
    Rustgi, Vinod
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (02)
12345